Condition
Relapsed/Refractory Non-Hodgkin's Lymphoma
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Withdrawn1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04134247Phase 4UnknownPrimary
Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL
NCT02095574Phase 1WithdrawnPrimary
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Showing all 2 trials